Conviction
$ Value
$104K
Shares
1,000
Price
$104
Filed
May 13
▶ Why this score? (6/10)
- ✓ Open market buy (+3)
- ✓ C-suite insider (+2)
- ✓ Not a 10b5-1 plan (+1)
Insider
Name
Espinoza Octavio
Title
Chief Financial Officer
CIK
0001905248
Roles
Transaction Details
Transaction Date
2025-05-09
Code
P
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
27,432
Footnotes
The reporting person's purchase of Ligand Pharmaceuticals Incorporated ("Ligand") common stock reported herein might be deemed matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,500 shares, with the reporting person's sale of 2,104 shares of Ligand common stock at the highest price of $116.71 per share on December 23, 2024. Accordingly, the reporting person has paid to Ligand, $18,975, representing the full amount of any profit realized if this were to be deemed to be a short-swing transaction. | The total includes 69 shares acquired on December 31, 2024, through the Issuer's Employee Stock Purchase Plan (ESPP).
Filing Info
Espinoza Octavio's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-03-02 | LGND | A | $0 |
| 2026-03-02 | LGND | A | $0 |
| 2025-12-31 | LGND | J | $765 |
| 2025-12-16 | LGND | M | $63K |
| 2025-12-16 | LGND | M | $4K |
| 2025-12-16 | LGND | M | $18K |
| 2025-12-16 | LGND | M | $60K |
| 2025-12-16 | LGND | M | $19K |
| 2025-12-16 | LGND | M | $0 |
| 2025-12-16 | LGND | M | $0 |
Other Insiders at LGND (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| LAMATTINA JOHN L | — | $434K | 2026-03-06 |
| KOZARICH JOHN W | — | $94K | 2026-04-01 |
|
Davis Todd C
Chief Executive Officer
|
— | — | 2026-03-02 |
| Sabba Stephen L | — | $208K | 2026-03-23 |
|
Espinoza Octavio
Chief Financial Officer
|
— | — | 2026-03-02 |
|
Reardon Andrew
CLO & Secretary
|
— | $1.0M | 2026-04-01 |